FDA Granted Pediatric Disease Designation for OXi-4503
September 16, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics...